The DEA has initiated temporary scheduling procedures for placement of the synthetic opioid isotonitazene in Schedule I (85 Fed. Reg. 36819, June 18, 2020). The substance has not been approved in the United States as a pharmaceutical drug, but there are reports that it has been widely used as an illicit substitute for Schedule I etonitazene in this country and elsewhere. The agenc... Read More